Impact of antioxidants in improving semen parameters like count, motility and DNA fragmentation in sub-fertile males: a randomized, double-blind, placebo-controlled clinical trial.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Ameet Patki, Rohit Shelatkar, Monica Singh, Sweta Agarwal, Venugopal M, Shashikant Umbardand, Apoorva Reddy, Priya Kannan, Srilatha Gorthi, Gautam Khastgir, Anita Kulshreshtha, Gayatri Ganu
{"title":"Impact of antioxidants in improving semen parameters like count, motility and DNA fragmentation in sub-fertile males: a randomized, double-blind, placebo-controlled clinical trial.","authors":"Ameet Patki,&nbsp;Rohit Shelatkar,&nbsp;Monica Singh,&nbsp;Sweta Agarwal,&nbsp;Venugopal M,&nbsp;Shashikant Umbardand,&nbsp;Apoorva Reddy,&nbsp;Priya Kannan,&nbsp;Srilatha Gorthi,&nbsp;Gautam Khastgir,&nbsp;Anita Kulshreshtha,&nbsp;Gayatri Ganu","doi":"10.12793/tcp.2023.31.e6","DOIUrl":null,"url":null,"abstract":"<p><p>Male infertility is solely responsible for 20-30% of infertility cases. Oxidative damage of sperm DNA is positively linked with oligoasthenoteratozoospermia (OAT), and male infertility. The antioxidants are being explored worldwide to combat OAT, sperm DNA fragmentation and reactive oxygen species. The objective of the study was to assess the effectiveness of an antioxidant blend in improving sperm count, semen parameters and reducing DNA fragmentation index (DFI) in sub-fertile males. A prospective, double-blind, randomized, placebo-controlled trial was conducted in 300 sub-fertile males (25-45 years) from ten study sites in India. Subjects were randomized in either the antioxidant blend treatment group or placebo group. We assessed changes in sperm count, motility, normal morphology, semen volume, and percent DFI before and after treatment (90 days). To further stratify data on different criteria <i>post hoc</i> analysis was performed. Statistical analysis was performed using SPSS 10.0 software. There were improvements in sperm count, semen volume, sperm motility, and sperm normal morphology in the treatment group. There was improvement in sperm count in severe oligospermia subjects (sperm count < 5 million/mL, 5-10 million/mL, 10.1-15 million/mL), and high-extremely higher baseline DFI (20-30%, 31-40% and above 40%), as per <i>post hoc</i> analysis. There was no premature discontinuation and adverse events were reported during the study, indicating safety and well-tolerability of treatment. Study results confirmed the well-researched fact of antioxidants being effective to reduce oxidative stress and thus improve sperm DNA integrity and also improved semen parameters in males aged 40 and above.</p><p><strong>Trial registration: </strong>Clinical Trials Registry-India Identifier: CTRI/2020/12/029590.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/98/tcp-31-28.PMC10079508.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational and Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12793/tcp.2023.31.e6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Male infertility is solely responsible for 20-30% of infertility cases. Oxidative damage of sperm DNA is positively linked with oligoasthenoteratozoospermia (OAT), and male infertility. The antioxidants are being explored worldwide to combat OAT, sperm DNA fragmentation and reactive oxygen species. The objective of the study was to assess the effectiveness of an antioxidant blend in improving sperm count, semen parameters and reducing DNA fragmentation index (DFI) in sub-fertile males. A prospective, double-blind, randomized, placebo-controlled trial was conducted in 300 sub-fertile males (25-45 years) from ten study sites in India. Subjects were randomized in either the antioxidant blend treatment group or placebo group. We assessed changes in sperm count, motility, normal morphology, semen volume, and percent DFI before and after treatment (90 days). To further stratify data on different criteria post hoc analysis was performed. Statistical analysis was performed using SPSS 10.0 software. There were improvements in sperm count, semen volume, sperm motility, and sperm normal morphology in the treatment group. There was improvement in sperm count in severe oligospermia subjects (sperm count < 5 million/mL, 5-10 million/mL, 10.1-15 million/mL), and high-extremely higher baseline DFI (20-30%, 31-40% and above 40%), as per post hoc analysis. There was no premature discontinuation and adverse events were reported during the study, indicating safety and well-tolerability of treatment. Study results confirmed the well-researched fact of antioxidants being effective to reduce oxidative stress and thus improve sperm DNA integrity and also improved semen parameters in males aged 40 and above.

Trial registration: Clinical Trials Registry-India Identifier: CTRI/2020/12/029590.

Abstract Image

Abstract Image

Abstract Image

抗氧化剂对改善不育男性精液数量、活力和DNA片段等参数的影响:一项随机、双盲、安慰剂对照的临床试验。
男性不育症是20-30%不育症的唯一原因。精子DNA的氧化损伤与少弱无畸形精子症(OAT)和男性不育呈正相关。世界各地都在探索抗氧化剂,以对抗OAT、精子DNA断裂和活性氧。该研究的目的是评估抗氧化剂混合物在提高精子数量、精液参数和降低低生育能力男性DNA片段化指数(DFI)方面的有效性。一项前瞻性、双盲、随机、安慰剂对照试验在印度10个研究地点的300名低生育能力男性(25-45岁)中进行。受试者被随机分为抗氧化剂混合治疗组和安慰剂组。我们评估了治疗前后(90天)精子数量、活力、正常形态、精液量和DFI百分比的变化。为了进一步对不同标准的数据进行分层,进行了事后分析。采用SPSS 10.0软件进行统计学分析。治疗组在精子数量、精液量、精子活力和精子正常形态方面均有改善。根据事后分析,严重少精症患者的精子数量(精子数量< 500万/mL、5-10万/mL、1010 -15万/mL)和高-极高基线DFI(20-30%、31-40%和高于40%)均有改善。在研究期间没有过早停药和不良事件的报道,表明治疗的安全性和良好的耐受性。研究结果证实了一个经过充分研究的事实,即抗氧化剂可以有效地减少氧化应激,从而改善精子DNA的完整性,并改善40岁及以上男性的精液参数。试验注册:印度临床试验注册中心标识符:CTRI/2020/12/029590。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Translational and Clinical Pharmacology
Translational and Clinical Pharmacology Medicine-Pharmacology (medical)
CiteScore
1.60
自引率
11.10%
发文量
17
期刊介绍: Translational and Clinical Pharmacology (Transl Clin Pharmacol, TCP) is the official journal of the Korean Society for Clinical Pharmacology and Therapeutics (KSCPT). TCP is an interdisciplinary journal devoted to the dissemination of knowledge relating to all aspects of translational and clinical pharmacology. The categories for publication include pharmacokinetics (PK) and drug disposition, drug metabolism, pharmacodynamics (PD), clinical trials and design issues, pharmacogenomics and pharmacogenetics, pharmacometrics, pharmacoepidemiology, pharmacovigilence, and human pharmacology. Studies involving animal models, pharmacological characterization, and clinical trials are appropriate for consideration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信